These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 12100505

  • 1. Concomitant basiliximab with low-dose calcineurin inhibitors in children post-liver transplantation.
    Arora N, McKiernan PJ, Beath SV, deVille de Goyet J, Kelly DA.
    Pediatr Transplant; 2002 Jun; 6(3):214-8. PubMed ID: 12100505
    [Abstract] [Full Text] [Related]

  • 2. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody.
    Gonwa TA, Mai ML, Smith LB, Levy MF, Goldstein RM, Klintmalm GB.
    Clin Transplant; 2002 Apr; 16(2):144-9. PubMed ID: 11966785
    [Abstract] [Full Text] [Related]

  • 3. Belatacept for kidney transplant recipients.
    Masson P, Henderson L, Chapman JR, Craig JC, Webster AC.
    Cochrane Database Syst Rev; 2014 Nov 24; 2014(11):CD010699. PubMed ID: 25416857
    [Abstract] [Full Text] [Related]

  • 4. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G, Walsh G, Deshpande P, Koffman G.
    Nephrol Dial Transplant; 2002 Jul 24; 17(7):1304-9. PubMed ID: 12105256
    [Abstract] [Full Text] [Related]

  • 5. Basiliximab with delayed introduction of calcineurin inhibitors as a renal-sparing protocol following liver transplantation in children with renal impairment.
    Mouzaki M, Yap J, Avinashi V, Babu A, Fu A, Deangelis M, Van Roestel K, Ghanekar A, Kamath B, Avitzur Y, Fecteau A, Jones N, Ling S, Grant D, Ng V.
    Pediatr Transplant; 2013 Dec 24; 17(8):751-6. PubMed ID: 24118898
    [Abstract] [Full Text] [Related]

  • 6. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
    Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B.
    Transplantation; 2001 May 15; 71(9):1282-7. PubMed ID: 11397963
    [Abstract] [Full Text] [Related]

  • 7. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation.
    Arora-Gupta N, Davies P, McKiernan P, Kelly DA.
    Pediatr Transplant; 2004 Apr 15; 8(2):145-50. PubMed ID: 15049794
    [Abstract] [Full Text] [Related]

  • 8. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A.
    Paediatr Drugs; 2003 Apr 15; 5(10):699-716. PubMed ID: 14510627
    [Abstract] [Full Text] [Related]

  • 9. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR.
    J Surg Res; 2007 Apr 15; 138(2):198-204. PubMed ID: 17292404
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP.
    Lancet; 1997 Oct 25; 350(9086):1193-8. PubMed ID: 9652559
    [Abstract] [Full Text] [Related]

  • 12. Initial immunosuppression with or without basiliximab: a comparative study.
    Martín-Mateos RM, Graus J, Albillos A, Arocena C, Rodríguez Gandía MA, Blesa C, García-Hoz F, García González M, García-Alonso FJ, Bárcena R.
    Transplant Proc; 2012 Nov 25; 44(9):2570-2. PubMed ID: 23146457
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
    Gabardi S, Catella J, Martin ST, Perrone R, Chandraker A, Magee CC, McDevitt-Potter LM.
    Ann Pharmacother; 2011 Sep 25; 45(9):e48. PubMed ID: 21811001
    [Abstract] [Full Text] [Related]

  • 15. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
    Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, Scudamore CH, Cuervas-Mons V, Metselaar HJ, Prestele H, Girault D.
    Liver Transpl; 2002 Feb 25; 8(2):123-31. PubMed ID: 11862588
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients.
    Vester U, Kranz B, Testa G, Malagò M, Beelen D, Broelsch CE, Hoyer PF.
    Pediatr Transplant; 2001 Aug 25; 5(4):297-301. PubMed ID: 11472610
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT.
    Goralczyk AD, Schnitzbauer A, Tsui TY, Ramadori G, Lorf T, Obed A.
    BMC Surg; 2010 Apr 09; 10():15. PubMed ID: 20380712
    [Abstract] [Full Text] [Related]

  • 19. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK, Wu FL, Lai IR, Lee CY, Hu RH, Lee PH.
    Int J Artif Organs; 2009 Jun 09; 32(6):371-80. PubMed ID: 19670189
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.